Analysts expect that ABIOMED, Inc. (NASDAQ:ABMD) will announce $0.93 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for ABIOMED’s earnings, with estimates ranging from $0.86 to $1.01. ABIOMED posted earnings per share of $0.81 in the same quarter last year, which would suggest a positive year-over-year growth rate of 14.8%. The business is expected to report its next earnings results on Thursday, November 7th.

According to Zacks, analysts expect that ABIOMED will report full year earnings of $4.29 per share for the current fiscal year, with EPS estimates ranging from $4.19 to $4.43. For the next year, analysts forecast that the company will post earnings of $5.39 per share, with EPS estimates ranging from $4.86 to $6.24. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow ABIOMED.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.01. ABIOMED had a net margin of 32.35% and a return on equity of 19.84%. The firm had revenue of $207.70 million during the quarter, compared to analysts’ expectations of $210.96 million. During the same period last year, the company posted $1.95 EPS. The company’s quarterly revenue was up 15.4% compared to the same quarter last year.

Several analysts recently weighed in on ABMD shares. ValuEngine upgraded ABIOMED from a “sell” rating to a “hold” rating in a research note on Wednesday, September 4th. William Blair reaffirmed a “buy” rating on shares of ABIOMED in a research note on Friday, August 2nd. Guggenheim cut ABIOMED from a “buy” rating to a “neutral” rating in a research report on Friday, August 2nd. TheStreet cut ABIOMED from a “b-” rating to a “c+” rating in a research report on Thursday, August 22nd. Finally, BTIG Research lowered ABIOMED from a “buy” rating to a “neutral” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $316.50.

ABMD stock traded down $0.75 during midday trading on Friday, hitting $191.07. The stock had a trading volume of 484,606 shares, compared to its average volume of 634,107. The firm has a market cap of $8.70 billion, a price-to-earnings ratio of 53.08, a price-to-earnings-growth ratio of 1.65 and a beta of 0.45. The business has a 50-day moving average of $207.00 and a two-hundred day moving average of $261.59. ABIOMED has a 52-week low of $180.00 and a 52-week high of $459.75.

In other news, COO David M. Weber sold 8,095 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $206.26, for a total value of $1,669,674.70. Following the completion of the transaction, the chief operating officer now directly owns 132,913 shares in the company, valued at $27,414,635.38. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 3.40% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in shares of ABIOMED by 102.1% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 35,669 shares of the medical equipment provider’s stock worth $9,291,000 after acquiring an additional 18,016 shares during the period. Rehmann Capital Advisory Group lifted its stake in ABIOMED by 698.1% in the second quarter. Rehmann Capital Advisory Group now owns 423 shares of the medical equipment provider’s stock valued at $110,000 after buying an additional 370 shares during the last quarter. Treasurer of the State of North Carolina lifted its stake in ABIOMED by 8.6% in the second quarter. Treasurer of the State of North Carolina now owns 18,473 shares of the medical equipment provider’s stock valued at $4,812,000 after buying an additional 1,460 shares during the last quarter. Nomura Holdings Inc. boosted its holdings in shares of ABIOMED by 95.5% in the second quarter. Nomura Holdings Inc. now owns 7,709 shares of the medical equipment provider’s stock valued at $2,043,000 after acquiring an additional 3,765 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of ABIOMED by 9.4% in the second quarter. BlackRock Inc. now owns 3,389,676 shares of the medical equipment provider’s stock valued at $882,977,000 after acquiring an additional 290,358 shares during the period. Institutional investors own 91.53% of the company’s stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: What Are Treasury Bonds?

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.